{"title":"Exploring the Functional and Prognostic Significance of miR-217 in Uterine Corpus Endometrial Carcinoma.","authors":"Guizhen Lyu, Dongbing Li","doi":"10.2174/0109298673365101250404105130","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The presence of microRNA-217 (miR-217) has been observed across various malignancies. However, its specific contribution to uterine corpus endometrial carcinoma (UCEC) is yet to be fully understood.</p><p><strong>Objective: </strong>We aimed to explore the role of miR-217 in UCEC.</p><p><strong>Methods: </strong>Clinical and genomic data, alongside prognostic insights, for UCEC patients were sourced from the TCGA repository. A suite of statistical tools, including the Kruskal-Wallis test, Wilcoxon sign-rank test, and logistic regression, was deployed to scrutinize the correlation between miR-217 levels and clinical profiles. The Kaplan-Meier method was applied to chart survival curves, thereby assessing the prognostic implications of miR-217 levels and its target genes in UCEC. TargetScan, PicTar, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were conducted to uncover the functional envelope of miR-217 target genes. An immune infiltration analysis provided further context to the role of miR-217 in immune modulation. We validated the expression of miR-217 in cell lines.</p><p><strong>Results: </strong>miR-217 demonstrates atypical expression across a spectrum of cancers, including UCEC. The expression of miR-217 in the Mixed&Serous subtypes of UCEC is significantly higher than that in the Endometrioid subtype (p = 0.008). The presence of miR-217 is associated with adverse impacts on overall survival (OS) and disease-specific survival (DSS) in UCEC patients, with hazard ratios (HR) of 1.55 (95% CI: 1.00-2.38, p = 0.048) and 2.05 (95% CI: 1.19-3.53, p = 0.010), indicating statistical significance. The prognostic significance of miR-217 in UCEC is highlighted by its status as a standalone indicator of patient outcomes. Diminished expression of genes targeted by miR-217, such as BCL2, DYRK1A, IGF1R, NDN, and NHS, is correlated with diminished OS in UCEC. miR-217 is intricately involved in the pathogenesis of UCEC, potentially through involvement in pathways like the AMPK signaling and FoxO signaling pathways. The expression of miR-217 in UCEC is significantly correlated with the infiltration level of some immune cells. Notably, in cell lines derived from UCEC, miR-217 expression is markedly increased.</p><p><strong>Conclusion: </strong>The up-regulation of miR-217 is strongly linked to an adverse prognosis in UCEC patients, suggesting its potential as a prognostic biomarker and a predictor of immunotherapy response in UCEC patients.</p>","PeriodicalId":10984,"journal":{"name":"Current medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0109298673365101250404105130","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The presence of microRNA-217 (miR-217) has been observed across various malignancies. However, its specific contribution to uterine corpus endometrial carcinoma (UCEC) is yet to be fully understood.
Objective: We aimed to explore the role of miR-217 in UCEC.
Methods: Clinical and genomic data, alongside prognostic insights, for UCEC patients were sourced from the TCGA repository. A suite of statistical tools, including the Kruskal-Wallis test, Wilcoxon sign-rank test, and logistic regression, was deployed to scrutinize the correlation between miR-217 levels and clinical profiles. The Kaplan-Meier method was applied to chart survival curves, thereby assessing the prognostic implications of miR-217 levels and its target genes in UCEC. TargetScan, PicTar, Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were conducted to uncover the functional envelope of miR-217 target genes. An immune infiltration analysis provided further context to the role of miR-217 in immune modulation. We validated the expression of miR-217 in cell lines.
Results: miR-217 demonstrates atypical expression across a spectrum of cancers, including UCEC. The expression of miR-217 in the Mixed&Serous subtypes of UCEC is significantly higher than that in the Endometrioid subtype (p = 0.008). The presence of miR-217 is associated with adverse impacts on overall survival (OS) and disease-specific survival (DSS) in UCEC patients, with hazard ratios (HR) of 1.55 (95% CI: 1.00-2.38, p = 0.048) and 2.05 (95% CI: 1.19-3.53, p = 0.010), indicating statistical significance. The prognostic significance of miR-217 in UCEC is highlighted by its status as a standalone indicator of patient outcomes. Diminished expression of genes targeted by miR-217, such as BCL2, DYRK1A, IGF1R, NDN, and NHS, is correlated with diminished OS in UCEC. miR-217 is intricately involved in the pathogenesis of UCEC, potentially through involvement in pathways like the AMPK signaling and FoxO signaling pathways. The expression of miR-217 in UCEC is significantly correlated with the infiltration level of some immune cells. Notably, in cell lines derived from UCEC, miR-217 expression is markedly increased.
Conclusion: The up-regulation of miR-217 is strongly linked to an adverse prognosis in UCEC patients, suggesting its potential as a prognostic biomarker and a predictor of immunotherapy response in UCEC patients.
期刊介绍：
Aims & Scope
Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
